Lupkynis is a medicine that is used for a specific kidney disease called lupus nephritis. Lupus nephritis is a kidney condition that affects people with systemic lupus erythematosus (SLE). SLE is an ...

Review authors suggested guidelines to help in standardizing future lupus nephritis studies. Heterogeneity in lupus nephritis (LN) trial design substantially hinders interpretation of studied drugs’ ...

Lupus nephritis is one of the most serious complications of systemic lupus erythematosus (SLE). It occurs when the immune system mistakenly attacks the kidneys, leading to inflammation and possibly to ...

Until biomarkers that can predict treatment response emerge, early and aggressive treatment is recommended in lupus nephritis ...

Panelists discuss the significant clinical and economic burdens of lupus nephritis, including the increased risk of kidney failure and death, and provide current statistics on the prevalence and ...

Medical experts illustrate characteristics in the presentation of lupus nephritis. Jorge Larranaga, MD: Lupus nephritis can present in several ways. Lupus may take up to 6 years to be diagnosed. About ...

T-cell profiles derived from blood and renal biopsy may be novel biomarkers of lupus nephritis treatment response, study findings suggest.

WASHINGTON — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications appear beneficial for people with systemic lupus erythematosus (SLE) and lupus nephritis, two new studies suggest. “The ...

Please provide your email address to receive an email when new articles are posted on . Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter ...

Low-grade proteinuria (< 1 g/24 h) did not predict better renal outcomes or treatment response in patients with lupus nephritis, despite being associated with milder disease phenotypes.

First-quarter revenue growth was driven by a 23% increase in net sales of Lupkynis, an oral treatment for adults with active lupus nephritis, a serious kidney disease. ・The biotech firm reiterated its ...